Upgrade to SI Premium - Free Trial

60 Degrees (SXTP)

0.92 -0.01 (1.08%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Form EFFECT 60 DEGREES PHARMACEUTICA August 26, 2026 6:05 AM - SEC Filing Form DEL AM 60 DEGREES PHARMACEUTICA August 17, 2026 11:32 AM - SEC Filing Form S-3 60 DEGREES PHARMACEUTICA August 14, 2026 4:31 PM - SEC Filing 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results August 14, 2026 3:47 PM - Globe NewsWire Form 10-Q 60 DEGREES PHARMACEUTICA For: Jun 30 August 14, 2026 3:35 PM - SEC Filing Form 8-K 60 DEGREES PHARMACEUTICA For: Aug 05 August 6, 2026 4:10 PM - SEC Filing Form SCHEDULE 13G 60 DEGREES PHARMACEUTICA Filed by: Lind Global Fund III LP August 5, 2026 5:12 PM - SEC Filing Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 30 August 4, 2026 4:45 PM - SEC Filing 60 Degrees Pharmaceuticals raises $1M in private placement July 30, 2026 2:23 PM - StreetInsider 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules July 30, 2026 2:23 PM - Globe NewsWire Form 3 60 DEGREES PHARMACEUTICA For: Jul 22 Filed by: Knight Therapeutics Inc. July 29, 2026 4:07 PM - SEC Filing Form SCHEDULE 13G 60 DEGREES PHARMACEUTICA Filed by: Knight Therapeutics Inc. July 29, 2026 4:06 PM - SEC Filing 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 July 29, 2026 4:03 PM - Globe NewsWire Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 20 July 20, 2026 4:06 PM - SEC Filing Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 07 July 9, 2026 4:06 PM - SEC Filing 60 Degrees Pharma signs option deal with Florida State for tick disease compound July 8, 2026 8:01 AM - StreetInsider 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases July 8, 2026 8:01 AM - Globe NewsWire Form DEF 14A 60 DEGREES PHARMACEUTICA For: Aug 05 July 2, 2026 4:06 PM - SEC Filing 60 Degrees Pharma gets safety board clearance for babesiosis trial July 1, 2026 8:02 AM - StreetInsider 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue July 1, 2026 8:02 AM - Globe NewsWire Form 4 60 DEGREES PHARMACEUTICA For: Jun 12 Filed by: DOW GEOFFREY S June 15, 2026 4:51 PM - SEC Filing 60 Degrees Pharmaceuticals licenses Australian chestnut patent June 11, 2026 8:03 AM - StreetInsider 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement June 11, 2026 8:03 AM - Globe NewsWire Form PRE 14A 60 DEGREES PHARMACEUTICA For: Jun 08 June 8, 2026 5:14 PM - SEC Filing Full Article List